Abstract：Objective To explore the polarity protein Par3 (Par3 protein) in chronic cervicitis, cervical intraepithelial neoplasia Ⅱ-Ⅲ (CINⅡ-Ⅲ), cervical squamous cell carcinoma (CSCC) and the expression differences in metastasis lymph node tissue and its clinical significance. Methods From January 2016 to December 2017, Xinjiang Medical University First Affiliated Hospital of CINⅡ-Ⅲ CSCC, as well as the line of hysterectomy for benign disease patients with cervical tissue samples archived paraffin embedding tissue, a total of 93 cases were seleeted from Department of Gynaecology. Among them 14 cases of chronic cervicitis, 36 cases of CINⅡ-Ⅲ, and 43 cases of cervical squamous cell carcinoma. Another 7 cases of cervical squamous cell carcinoma lymph node metastasis tissue samples. The expression of polar protein Par3 in the above tissues was detected by immunohistochemical staining. Results The positive expression rate of Par3 protein in chronic cervicitis, CINⅡ-Ⅲ, CSCC and metastasis lymph node tissues were 100.0% (14/14), 97.2% (35/36), 62.8% (27/43), 0 respectively, the differences between each group had statistical significance (P ＜ 0.05). The Par3 protein expression was 100% (7/7) in the high differentiation group of CSCC, while the expression was down-regulated to 55.6% (20/36) in the low and medium differentiation group, with statistically significant difference (P ＜ 0.05). They were grouped according to whether lymph node metastasis had occurred (7 cases in lymph node metastasis group 36 cases in the group without lymph node metastasis. The positive expression rate of Par3 protein in cervical tissues of the lymph node metastasis group was 28.6% (2/7), while that of the non-metastasis group was 58.3% (21/36), with statistically significant difference (P ＜ 0.05). The low expression of Par3 protein was correlated with histological differentiation and lymph node metastasis, and the difference was statistically significant (P ＜ 0.05). Conclusion Polarity protein Par3 in chronic cervicitis, CINⅡ-Ⅲ CSCC and are differentially expressed, the expression of CSCC is down-regulated, and its abnormal low expression is related to the occurrence and development of CSCC, which can be used as an early warning indicator to judge the development of cervical intraepithelial neoplasia into CSCC, as well as an indicator to judge the malignancy degree and prognosis of CSCC.
[1] Yang BH，Bray FI，Parkin DM，et al. Cervical cancer as a priority for prevention in different world regions：anevaluation using years of life lost [J]. Int J Cance，2004，109（3）：418-424.
[2] Mezei AK，Armstrong HL，Pedersen HN，et al. Cost-effectiveness of cervical cancer screening methods in low-and middle-income countries：A systematic review [J]. Int J Cancer，2017，141（3）：437-446.
[3] Etienne-M anneville S. Polarity proteins in m igration and invasion [J]. Oncogene，2008，27（55）：6970-6980.
[4] Xue B，Krishnamurthy K，Allred DC，et al. Loss of Par3 promotes breast cancer metastasis by compromising cell cell cohesion [J]. Nat Cell Biol，2013：15（2）：189-200.
[5] Lin WH，Asmann YW，Anastasiadis PZ. Expression of polaritv genes in human cancer [J]. Cancer Inforrn，2015，14（suppl 3）：15-28.
[6] Zhou PJ，Wang X，An N，et al. Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes [J]. Oncogene，2019，38（12）：2192-2205.
[7] Guo X，Wallg M，Zhao Y，et al. Par3 reglulates invasion of pancreatic cancer cells via interaction with Tiaml [J]. Clin Exp Med，2016，16（3）：357-365.
[8] Zhou PJ，Xue W，Peng J，et al. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway [J]. J Exp Clin Cancer Res，2017，36（1）：139.
[9] Dugay F，Le Goff X，Rioux-Leclercq N，et al. Overexpression of the po1arity protein PAR-3 in clear cell renal cell carcinoma is associatedwith poor pmrognosis [J]. Int J cancer，2014，134（9）：2051-2060.
[10] 赵志华，田研，陈奎生.多发性骨髓瘤中c-myc和MDM2蛋白的表达及其临床意义[J].临床与实验病理学杂志2017，33（2）：165-168.
[11] Joberty G，Petersen C，Gao L，et al. The cell-polarity protein Par6links Par3 and atypical protein kinase C to Cdc42 [J]. Nat Cell Biol，2000，2（8）：531-539.
[12] Forteza R，Wald FA，Mashukova A，et al. Par-complex a PKC andPar3 cross -talk with innate immunity NF-κB pathway in epithelialcells [J]. Biol Open，2013，2（11）：1264-1269.
[13] Soriano EV，Ivanova ME，Fletcher G，et al. aPKC inhibition by Par3CR3 flanking regions controls substrate access and underpins Apical-junctional polarization [J]. Dev Cell，2016，38（4）：384-398.
[14] Soler AP，Miller RD，Laughlin KV，et al. Increased tight junctional permeability is associated with the development of coloncancer [J]. Carcinogenesis，1999，20（8）：1425-1431.
[15] Bilder D. Epithelial polarity and proliferation control：Links from the Drosophila neoplastic tumor suppressors [J]. Genes Dev 2004，18（16）：1909-1925.
[16] Gzalez-Mariscal L，Miranda J，Ortega-Olvera JM，et al. Involvement of Tight Junction Plaque Proteins in Cancer [J]. Current Pathobiology Reports，2016（3）：1-17.
[17] Guyer RA，Macara IG. Loss of the polarity protein PAR3 activates STAT3 signaling via an atypical protein kinase C（aPKC）/NF/κB/interleukin-6（IL-6） axis in mouse mammary cells [J]. J Biol Chem，2015，290（1/3）：8457-8468.
[18] Mescher M，Jeong P，Knapp SK，et al. The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma [J]. J Exp Med，2017，214（2）：339-358.
[19] Nakamura H，Nagasaka K，Kawana K，et al. Expression of Par3 polarity Protein correlates with poor prognosis in ovarian cancer [J]. Bmc Cancer，2016，16（1）897.
[20] Zheng JH，Jiao SJ，Na L，et al. Defective expression of polarity protien Par3 promotes cervical tumorigenesis and metastasis [J]. Eur J Gynaecol Oncol，2017，38（2）：199-206.
2019, Vol. 16 
京公网安备 11010502046598号